Italian registry to track Real-World use of cholesterol drug
NCT ID NCT07375225
First seen Jan 31, 2026 · Last updated May 08, 2026 · Updated 15 times
Summary
This study is a registry that will follow 1,500 Italian adults taking alirocumab 300 mg for high cholesterol. Researchers want to see how well patients stick with the treatment over time and how much it lowers their LDL (bad) cholesterol in everyday life. The study does not test a new drug but gathers real-world data on adherence, effectiveness, and safety.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HYPERCHOLESTEROLAEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Federico II University of Naples, Department of Advanced Biomedical Sciences
RECRUITINGNaples, Napoli, 80131, Italy
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.